MedTrace Logo

Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

NCT05284552 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-11

No results posted yet for this study

Summary

Background:

Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant. Earlier studies have mainly investigated the antineoplastic effects of tinzaparin in animal models and in human cell-lines. In this pilot study the aim is to examine the potential antitumoral effects of tinzaparin in vivo in women with epithelial ovarian cancer (EOC).

Study objectives:

Primary objective: The primary objective of the study is to evaluate the effects of tinzaparin on changes in levels of CA-125 in EOC patients who receive neoadjuvant chemotherapy (NACT).

Secondary objectives: The secondary objective of the study is to explore the impact of tinzaparin on the dynamic of a spectrum of immunological and coagulation factors in EOC patients who receive NACT. Besides, the compliance of tinzaparin injections and adverse events caused by tinzaparin will be described.

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

Tinzaparin Injectable Solution

Subcutaneous injection

Sponsors & Collaborators

  • Region Jönköping County

    collaborator OTHER_GOV

  • Västervik Hospital

    collaborator OTHER

  • Vastra Gotaland Region

    collaborator OTHER_GOV

  • Region Västerbotten

    collaborator OTHER_GOV

  • University Hospital, Linkoeping

    lead OTHER

Principal Investigators

  • Preben Kjölhede, MD, PhD · University Hospital, Linkoeping

  • Gabriel Lindahl, MD, PhD · University Hospital, Linkoeping

  • Anna-Clara Spetz Holm, MD, PhD · University Hospital, Linkoeping

  • Anna Karlsson, MD · University Hospital, Linkoeping

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-12
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05284552 on ClinicalTrials.gov